Literature DB >> 18287297

PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine.

Cecilia Sorhouet Pereira1,2, Mabel Regueira1, Marta Mollerach2.   

Abstract

Identification of Neisseria meningitidis PorA types remains important, as the PorA protein is a major immunogenic component of several meningococcal vaccines under development. In this study, 191 N. meningitidis serogroup B isolates collected in Argentina through active laboratory-based surveillance from 2001 to 2003 were serosubtyped. Nucleotide sequences of the porA variable region 1 (VR1) and VR2 regions were determined in 52 non-serosubtypeable isolates. A substantial number of distinct VR types were identified, and a new VR2 variant from the P1.16 family was described. This is the first report describing PorA types in N. meningitidis serogroup B isolates in Argentina. Furthermore, the wide diversity of subtypes detected by serosubtyping and genosubtyping reveals the difficulty in designing a useful outer-membrane vaccine applicable in this country. A possible mechanism responsible for altered PorA expression was analysed in two PorA types.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287297     DOI: 10.1099/jmm.0.47631-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina.

Authors:  Adriana M Efron; Cecilia Sorhouet; Celia Salcedo; Raquel Abad; Mabel Regueira; Julio A Vázquez
Journal:  J Clin Microbiol       Date:  2009-04-08       Impact factor: 5.948

Review 2.  The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape.

Authors:  M A P Sáfadi; S González-Ayala; A Jäkel; H Wieffer; C Moreno; A Vyse
Journal:  Epidemiol Infect       Date:  2012-08-09       Impact factor: 2.451

Review 3.  The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

Authors:  Michael W Shea
Journal:  Ann Med Surg (Lond)       Date:  2013-11-04

4.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Estimation of the real burden of invasive meningococcal disease in Argentina.

Authors:  J A Gómez; P Wetzler Malbrán; G Vidal; M Seoane; N D Giglio
Journal:  Epidemiol Infect       Date:  2019-11-29       Impact factor: 2.451

6.  Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010.

Authors:  Ana Belén Ibarz-Pavón; Ana Paula Lemos; Maria Cecilia Gorla; Mabel Regueira; Jean-Marc Gabastou
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

7.  Phenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010.

Authors:  Cecilia Sorhouet-Pereira; Adriana Efron; Paula Gagetti; Diego Faccone; Mabel Regueira; Alejandra Corso; Jean-Marc Gabastou; Ana Belén Ibarz-Pavón
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.